PPARG and breast carcinoma: Despite the large number of preclinical studies investigating the role of ligand-activated PPARγ in breast cancer, only a few clinical trials have been conducted, and the results mainly address the potential of PPARγ agonists on breast cancer risk in healthy women and on the modulation of chemotherapy-related side effects in breast cancer patients.